FDG-PET/CT images of COVID-19: a comprehensive review

Minamimoto, Ryogo; Hotta, Masatoshi; Ishikane, Masahiro; Inagaki, Takeshi

doi:10.35772/ghm.2020.01056

Cited by 25 publications

(33 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) [15]. Furthermore, systemic inflammatory response to COVID-19 infection is known to cause significant damage to the brain, the lungs, and the bowel while also causing arterial and venous thrombosis [1,[15][16][17]. In recent years, the introduction of modern PET imaging instruments which allow examining the entire body with a single data acquisition is ideally suited for examining patients with SARS-CoV-2 infection ( Fig.…”

mentioning

confidence: 99%

The critical role of FDG-PET/CT imaging in assessing systemic manifestations of COVID-19 infection

Alavi

Werner

Gholamrezanezhad

2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

mentioning

confidence: 99%

The critical role of FDG-PET/CT imaging in assessing systemic manifestations of COVID-19 infection

Alavi

Werner

Gholamrezanezhad

2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…For COVID-19, hypermetabolic lymph nodes were commonly reported in the hilum, supraclavicular, and mediastinal area (Fig. 4 ) [ 49 , 52 , 53 ]. Compared with conventional imaging modalities, PET possessed higher sensitivity in detecting lymph node involvement [ 54 , 55 ].…”

Section: Pet In the Prognosis Evaluation Of Covid-19mentioning

confidence: 99%

“…Increased 18 F-FDG uptake was observed in mediastinal and hilar lymph nodes in the first scan 4 weeks after the symptom occurrence. The 18 F-FDG uptake was decreased in the second examination 4 weeks after first scan (reproduced by permission from reference [ 53 ]) …”

Section: Pet In the Prognosis Evaluation Of Covid-19mentioning

confidence: 99%

Positron emission tomography in the COVID-19 pandemic era

Jin

Luo

Qian

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has become a major public health problem worldwide since its outbreak in 2019. Currently, the spread of COVID-19 is far from over, and various complications have roused increasing awareness of the public, calling for novel techniques to aid at diagnosis and treatment. Based on the principle of molecular imaging, positron emission tomography (PET) is expected to offer pathophysiological alternations of COVID-19 in the molecular/cellular perspectives and facilitate the clinical management of patients. A number of PET-related cases and research have been reported on COVID-19 over the past one year. This article reviews the current studies of PET in the diagnosis and treatment of COVID-19, and discusses potential applications of PET in the development of management strategy for COVID-19 patients in the pandemic era.

show abstract

“…This flood of information calls for a careful extraction of the most salient findings, best accomplished by the process of systematic or narrative reviews of the literature. Reviews of radiological investigations of COVID-19 have naturally emphasized thoracic imaging [ 1 , 2 ], as have reviews of findings with [ 18 F]-FDG/PET [ 3 ]. A few studies have taken the broader perspective of compiling imaging findings by CT, PET, and MRI [ 4 ], while addressing the multi-systemic clinical manifestations of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

A comprehensive review of imaging findings in COVID-19 - status in early 2021

Afshar‐Oromieh

Prosch

Schaefer-Prokop

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Medical imaging methods are assuming a greater role in the workup of patients with COVID-19, mainly in relation to the primary manifestation of pulmonary disease and the tissue distribution of the angiotensin-converting-enzyme 2 (ACE 2) receptor. However, the field is so new that no consensus view has emerged guiding clinical decisions to employ imaging procedures such as radiography, computer tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, and in what measure the risk of exposure of staff to possible infection could be justified by the knowledge gained. The insensitivity of current RT-PCR methods for positive diagnosis is part of the rationale for resorting to imaging procedures. While CT is more sensitive than genetic testing in hospitalized patients, positive findings of ground glass opacities depend on the disease stage. There is sparse reporting on PET/CT with [18F]-FDG in COVID-19, but available results are congruent with the earlier literature on viral pneumonias. There is a high incidence of cerebral findings in COVID-19, and likewise evidence of gastrointestinal involvement. Artificial intelligence, notably machine learning is emerging as an effective method for diagnostic image analysis, with performance in the discriminative diagnosis of diagnosis of COVID-19 pneumonia comparable to that of human practitioners.

show abstract

FDG-PET/CT images of COVID-19: a comprehensive review

Cited by 25 publications

References 42 publications

The critical role of FDG-PET/CT imaging in assessing systemic manifestations of COVID-19 infection

The critical role of FDG-PET/CT imaging in assessing systemic manifestations of COVID-19 infection

Positron emission tomography in the COVID-19 pandemic era

A comprehensive review of imaging findings in COVID-19 - status in early 2021

Contact Info

Product

Resources

About